Vifor Pharma AG Logo

Vifor Pharma AG

Global leader in therapies for iron deficiency, anemia, and kidney disease.

VIFN | SW

Overview

Corporate Details

ISIN(s):
CH0364749348
LEI:
529900KO6CN2D9OE1F19
Country:
Switzerland
Address:
Rechenstrasse 37, 9014 St. Gallen

Description

Vifor Pharma AG, now operating as CSL Vifor, is a global pharmaceutical company that develops, manufactures, and markets products for severe and chronic diseases. It is a global leader in therapies for iron deficiency and iron deficiency anemia, with applications in heart failure, kidney disease, gastroenterology, and women's health. The company also has a strong and growing presence in nephrology, aiming to address the full spectrum of kidney disease through its joint company with Fresenius Medical Care Renal Pharma. Vifor Pharma's business model includes strategic global partnering, in-licensing, and the development of innovative therapies to address significant unmet medical needs.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Vifor Pharma AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Vifor Pharma AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Vifor Pharma AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-03-09 N/A Executive member Sell None 4,335,210.00 CHF
2022-03-09 N/A Non-Executive member Sell None 1,951,125.00 CHF
2022-03-09 N/A Non-Executive member Sell None 1,851,300.00 CHF
2022-03-09 N/A Executive member Sell None 1,535,160.00 CHF
2022-03-09 N/A Non-Executive member Sell None 1,450,515.00 CHF
2022-03-09 N/A Executive member Sell None 920,205.00 CHF
2022-03-09 N/A Executive member Sell None 530,310.00 CHF
2022-03-09 N/A Non-Executive member Sell None 382,140.00 CHF
2022-03-09 N/A Non-Executive member Sell None 330,495.00 CHF
2022-03-09 N/A Executive member Sell None 287,925.00 CHF

Peer Companies

Denali Therapeutics Inc. Logo
Develops therapies for neurodegenerative diseases using a blood-brain barrier platform.
United States of America
DNLI
Dermapharm Holding SE Logo
A manufacturer of patent-free branded pharmaceuticals and healthcare products.
Germany
DMP
Dermata Therapeutics, Inc. Logo
Medical dermatology company developing and commercializing OTC skin care products.
United States of America
DRMA
Design Therapeutics, Inc. Logo
Clinical-stage biopharma developing small molecule therapies for genetic diseases.
United States of America
DSGN
Deutsche Biotech Innovativ AG Logo
Develops therapeutics for serious diseases using innovative blood biomarkers.
Germany
DBI
DEVA HOLDİNG A.Ş. Logo
Develops, produces, and markets human medicines, APIs, and veterinary drugs globally.
Spain
DEVA
Devyser Diagnostics Logo
Develops DNA testing kits for hereditary diseases, oncology, and post-transplant monitoring.
Sweden
DVYSR
DexTech Medical AB Logo
Develops drug candidates for urological oncology, focusing on prostate cancer.
Sweden
DEX
DiaMedica Therapeutics Inc. Logo
Clinical-stage biopharma developing therapies for ischemic and vascular diseases.
United States of America
DMAC
Diamyd Medical AB (publ) Logo
A clinical-stage company developing precision therapies for autoimmune diabetes.
Sweden
DMYD

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.